No description available.

published_or_final_version / abstract / Paediatrics and Adolescent Medicine / Master / Master of Philosophy

Class of 2012 Abstract / Specific Aims: The purpose of this study was to evaluate the effectiveness of various post-operative prophylaxis methods in lung transplant patients by comparing the incidence of venous thromboembolism (VTE) before and after the implementation of a standardized hospital order set at the University of Arizona Medical Center (UAMC) in April 2007. Methods: Paper and electronic medical charts were retrospectively reviewed if patients had a lung transplant date between October 31, 2003 – October 31, 2010. A computerized database was used to collect demographic data, length of stay (LOS), comorbid conditions, prophylaxis type (including dose/frequency), and date/type of thromboembolic events in the post-operative period prior to discharge and up to 1-year post- discharge. Main Results: Ninety-two patient charts were included in the study with 35 charts in the pre-order set (“Before”) group and 57 charts in the post- order set (“After”) group. All baseline characteristics were similar between groups except age (mean age difference 8.1 yrs, p=0.003), use of mycophenolate (Before n=24, After n=54; p=0.002), and use of medications that increase risk of VTE (Before n=6, After n=2; p=0.05). The April 2007 protocol significantly increased the number of patients receiving any method of prophylaxis (p<0.0001). However, receiving prophlyaxis did not significantly reduce event rates or readmissions due to VTE. Conclusions: Although implementation of the April 2007 protocol did not significantly reduce VTE event rates and readmissions, VTE prophylaxis should continue to remain a priority. Adherence to the implemented protocol may reduce the number of patients left without effective methods of prophylaxis.

Background: Clopidogrel is commonly prescribed to cats with perceived increased risk of thromboembolic events, but little information exists regarding its antiplatelet effects. ObjectiveTo determine effects of clopidogrel on platelet responsiveness in cats with or without the A31P mutation in the MYBPC3 gene. A secondary aim was to characterize variability in feline platelet responses to clopidogrel. AnimalsFourteen healthy cats from a Maine Coon/outbred mixed Domestic cat colony: 8 cats homozygous for A31P mutation in the MYPBC3 gene and 6 wild-type cats without the A31P mutation. MethodsEx vivo study. All cats received clopidogrel (18.75 mg PO q24h) for 14 days. Before and after clopidogrel treatment, adenosine diphosphate (ADP)-induced P-selectin expression was evaluated. ADP- and thrombin-induced platelet aggregation was measured by optical aggregometry (OA). Platelet pVASP and ADP receptor response index (ARRI) were measured by Western blot analysis. ResultsPlatelet activation from cats with the A31P mutation was significantly (P = .0095) increased [35.55% (18.58-48.55) to 58.90% (24.85-69.90)], in response to ADP. Clopidogrel treatment attenuated ADP-induced P-selectin expression and platelet aggregation. ADP- and PGE(1)-treated platelets had a similar level of pVASP as PGE(1)-treated platelets after clopidogrel treatment. Clopidogrel administration resulted in significantly lower ARRI [24.13% (12.46-35.50) to 11.30% (-7.383 to 23.27)] (P = .017). Two of 13 cats were nonresponders based on OA and flow cytometry. Conclusion and Clinical ImportanceClopidogrel is effective at attenuating platelet activation and aggregation in some cats. Cats with A31P mutation had increased platelet activation relative to the variable response seen in wild-type cats.

No description available.

Diss. (sammanfattning) Uppsala : Uppsala universitet, 2006. / Härtill 4 uppsatser.

Thesis (MMedVet. (Diagnostic Imaging))--University of Pretoria, 2007. / Includes bibliographical references.

京都大学 / 0048 / 新制・課程博士 / 博士(医学) / 甲第21621号 / 医博第4427号 / 新制||医||1033(附属図書館) / 京都大学大学院医学研究科医学専攻 / (主査)教授 湊谷 謙司, 教授 佐藤 俊哉, 教授 横出 正之 / 学位規則第4条第1項該当 / Doctor of Medical Science / Kyoto University / DFAM

A unique and novel method to study thromboembolism by direct observation was developed. High-definition videos of thrombus formation and embolization were successfully obtained in miniature flow cells using in-vitro, non-invasive, real-time techniques. Critical parameters of thromboembolism such as thrombus growth rate, thrombus growth direction, shear force on the thrombus at embolization, and adhesion strength of the thrombus to the foreign surface were determined. Thrombus growth was found predominantly in two locations: 1) in the flow recirculation zone just after the trailing edge of the small tubes (53%) and 2) at the leading edge of the small tubes (47%). In the small tubes, thrombus volume and shear force acting on the thrombus increased in a power-law like function of time. In the large tubes, thrombus volume and shear force acting on the thrombus increased in a linear like function of time. The slope of thrombus growth rate in the small tubes was significantly greater than that in the large tubes. Thrombus growth direction was also estimated by tracking the thrombus center of mass with respect to time and typically ranged from 15 to 35 degrees from the direction of flow. According to observations, embolization seems to occur via two possible mechanisms: 1) complete detachment of the thrombus by sliding off the foreign surface or 2) partial embolization of the thrombus by internal tearing. The estimated shear force on the thrombus at embolization was determined and was significantly greater in the small tubes than in the large tubes. The adhesion strengths of thrombi were calculated for the small tubes using the shear force at embolization and the estimated thrombus attachment area and ranged from 9.63 to 28.83 N/m2 (mean = 16.24 ± 2.59 N/m2 95% confidence), which was in good agreement with published results of platelet retention experiments. An experimental series demonstrated that the developed method could be used to study the effects of controlled variables on thromboembolism parameters. In that series, heparin concentration in blood, blood flow rate, and device design were studied one variable at a time to test their effects on thrombus growth parameters and adhesion strength. Because of the small number of data, these preliminary results were statistically insignificant but pointed the way for future studies.

INTRODUÇÃO: A literatura demonstra que tromboembolismo venoso permanece como uma doença subdiagnosticada entre os pacientes hospitalizados, com aproximadamente 25% dos casos associados à internação. OBJETIVOS: Avaliar as doenças associadas ao desenvolvimento de tromboembolismo pulmonar (TEP) diagnosticado em autópsias, e demonstrar a frequência de TEP como causa do óbito ou fator contributivo. MÉTODOS: Estudo caso-controle retrospectivo, realizado no Instituto Central do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, no período de 1995 a 2004. Revisamos os relatórios diagnósticos das autópsias, identificando TEP fatal, quando TEP foi a causa de morte, e TEP não fatal, quando TEP foi doença associada. RESULTADOS: 1.506 pacientes (502 casos e 1.004 controles), 18.359 óbitos no período, média 2.040; 71,2% desses submetidos a autópsias. Observou-se importante declínio nas taxas de autópsias. De 1995-1999 (87,2%) e 2000-2004 (54,4%); p = 0,016. Dos 502 casos (3,8%), em 328 (2,5%) TEP foi causa de morte e 174 (1,3%), causa contributiva. Gênero: 51,6% homens e 48,4% mulheres. Idade: TEP fatal (328) vs controles (1.004), diferença estatisticamente significativa (p = 0,013). Condições prevalentes: câncer grupo, 31,4%, pós-operatório grupo, 17,2%, infecção grupo, 11,7%, e AVC grupo, 11%. Câncer de pulmão, 3,5%, câncer de cérebro e linfoma, 2,8%. Tempo de internação foi utilizado como indicador de imobilização. Outras doenças: AVCH (7,7%), pós-operatório de abdome (6,7%), pneumonia (5,9%), AVCI (3,1%) e pós-operatório vascular (4%) foram frequentes no grupo controle. Em contrapartida, aterosclerose (1,4%), ITU (1,2%), pós-operatório de ginecologia (0,8%), pós-operatório de obstetrícia (0,6%) e doença falciforme (0,6%) foram frequentes no grupo TEP. Cirrose, média de 14,9 dias de internação dos controles vs TEP com 4,4 dias (p < 0,001). Análise multivariada incluiu as condições com p 0,20 da univariada, idade e tempo de internação. Fator protetor para TEP: aneurisma de aorta (OR 0,02, IC 95% 0,46-0,56; p = 0,004), cirrose (OR 0,16, IC 95% 0,08-0,34; p < 0,001) e SIDA (OR 0,44, IC 95% 0,23-0,84; p = 0,013). Entretanto, AVCI (OR 1,82, IC 95% 1,04-3,19; p = 0,035), câncer de cérebro (OR 2,47, IC 95% 1,28-4,78; p = 0,007), câncer indeterminado (OR 3,12, IC 95% 1,01-9,68; p = 0,049), DPOC (OR 2,83, IC 95% 1,47-5,43; p = 0,002), ICC (OR 1,71, IC 95% 1,11-2,62; p = 0,015) e ITU (OR 4,34, IC 95% 1,05-17,82; p = 0,042) mostraram associação positiva com TEP. Idade vs TEP (OR 1,10, IC 95% 1,04-1,16; p = 0,001). Tempo de internação vs TEP (OR 1,19, IC 95% 1,05-1,36; p = 0,008). DISCUSSÃO: A porcentagem dos pacientes com TEP permanece inalterada, ocorrência de 4,1% e 3,4% no primero e no segundo períodos, com uma média de 3,8%. Em 50,4% dos pacientes não foi realizado o diagnóstico clínico de TEP. CONCLUSÃO: Constatou-se AVCI, câncer de cérebro indeterminado, DPOC, ICC e ITU com significância estatística e associação com TEP. Algumas fraquezas do presente estudo devem ser apuradas, e talvez explicarão as discordâncias com a literatura para algumas doenças. A identificação de fatores associados a TEP auxiliarão no diagnóstico precoce / INTRODUCTION: Literature shows that venous thromboembolism (VTE) remains as a sub-diagnostic disease among hospitalized patients, approximately 25% of all cases are associated to hospitalization. PURPOSE: Evaluate diseases associated to pulmonary thromboembolism (PE) development diagnosed in autopsies, and demonstrate the frequency of PE as cause of death or as a contributive factor. METHOD: The reports performed from 1995 to 2004 in a Brazilian tertiary referral medical school we reviewed for a retrospective study the autopsies diagnosis, identified as fatal PE, when PE was the cause of death and nonfatal PE, when PE was an associated disease. RESULTS: 1,506 patients (502 cases and 1004 controls), 18,359 deaths during the period, average 2,040; 71.2% of these were submitted to autopsies. It was observed an important decline in the autopsies rates. From 1995-1999 (87.2%) and 2000-2004 (54.4%) p = 0.016. From 502 cases (3.8%), 328 (2.5%) PE was the cause of death and 174 (1.3%) PE was contributive cause. Gender: 51.6% males and 48.4% females. AGE: fatal PE (328) vs controls (1,004) significant statistic difference (p = 0.013). Prevalent Conditions: cancer group, 31.4%, postsurgical group, 17.2%, infectious group, 11.7%, and CVA group, 11%. Pulmonary Cancer, 3.5%, Brain cancer and Lymphoma, 2.8%. Hospitalization period was taken as immobilization indicator. Other diseases: HCVA (7.7%), abdomen postsurgical (6.7%), pneumonia (5.9%), ICVA (3.1%) and vascular postsurgical (4%) were frequent in the control group. On the other hand, atherosclerosis (1.4%), UTI (Urinary Tract Infection) (1.2%), gynecology postsurgical (0.8%), obstetrics postsurgical (0.6%) and sickle cell anemia (0.6%) were frequent in the PE group. Cirrhosis, average of 14.9 hospitalization days of the controls vs PE with 4.4 days (p < 0.001). Logistic regression analysis includes the in univariated analysis with p 0.20, age and the hospitalization period. Protector factor for PE: Aortic aneurysm (OR 0.02, 95% CI 0.46-0.56; p = 0.004), cirrhosis (OR 0.16, 95% CI 0.08-0.34; p < 0.001) and SIDA (OR 0.44, 95% CI 0.23-0.84; p = 0.013). However, ICVA (OR 1.82, 95% CI 1.04-3.19; p = 0.035); brain cancer (OR 2.47, 95% CI 1.28-4.78; p = 0.007); undetermined cancer (OR 3.12, 95% CI 1.01-9.68, p= 0.049), COPD (OR 2.83, 95% CI 1.47-5.43; p = 0.002), CHF (OR 1.71, 95% CI 1.11-2.62; p = 0.015) and UTI (OR 4.34, 95% CI 1.05-17.82; p = 0.042), showed positive association with PE. Age vs PE (OR 1.10, 95% CI 1.04-1.16; p = 0.001). Hospitalization Period vs PE (OR 1.19, 95% CI 1.05-1.36; p = 0.008). DISCUSSION: The percentage of patients with PE remains unchanged, occurrence of 4.1% and 3.4% in the first and second periods, with an average of 3.8%. In 50.4% of the patients, the clinical diagnosis of TEP was not performed. CONCLUSION: We certified ICVA, brain cancer, undetermined cancer, COPD, CHF and UTI with significant association with PE. Some weaknesses of the present study should be refined, and maybe will explain the disagreement with the literature to some diseases. The identification of factors associated to PE will help in precocious diagnosis